Containment Development Engineer In-Vivo 
Pharmaceutical Technology
SEPTEMBER 14, 2022
As an autologous cell therapy, manufacturing the infusion product is a highly specialised process involving tumour harvest and the extraction and large-scale ex vivo expansion of TILs. The use of engineered immune cytokines that selectively induce the expansion of TILs is being investigated as an alternative to IL-2 stimulation.
The Pharma Data
JANUARY 11, 2021
a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
AUGUST 14, 2023
Over the past few decades, the incredible progress in personalised medicine has led to the development of life-saving cell and gene therapies (CGT). The agencies also have different requirements for the selection of healthy donors in the development of allogeneic cell therapies. billion in 2020 to $15.5
Drug Discovery World
OCTOBER 21, 2022
The advance could mean that future development of anti-cancer therapies won’t require the use of animal models. Triple-negative breast cancer cells can develop resistance to the chemotherapy drug doxorubicin. “Our 3D bioprinted breast cancer tumours. 3D bioprinted breast cancer tumours. New target for hard-to-treat breast cancer.
XTalks
AUGUST 17, 2020
Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. A growing area in the immunotherapy space is the development of biological modulators, which are genetically engineered proteins that target specific components of the immune system.
The Pharma Data
APRIL 22, 2023
Now, a research team at the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard John A. These backpacks are loaded with anti-inflammatory molecules that direct the carrier cells’ differentiation into anti-inflammatory cells in vivo. who is a Core Faculty member at the Wyss Institute.
The Pharma Data
DECEMBER 10, 2020
Many people who have been exposed to the “common cold” potentially develop adenovirus immunity: the immune system often attacks and disables these first-generation vaccines before they can activate the immune response to attack the SARS-CoV-2 virus. This blocking of viral replication was observed in both the lung and nasal passages.
Expert insights. Personalized for you.
246 
Let's personalize your content